Research Article| Volume 71, ISSUE 4, P666-672, October 2019

Download started.


Effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in patients with chronic hepatitis C previously treated with DAAs


      • Patients achieve high SVR12 rates with sofosbuvir/velpatasvir/voxilaprevir after prior DAA failures.
      • Sofosbuvir/velpatasvir/voxilaprevir is a very safe and well tolerated combination.
      • GT3 cirrhotic patients with previous treatment with NS5A-inhibitors are poor responders.
      • GT3 is the only factor that impacts SVR12 rates in retreatment with sofosbuvir/velpatasvir/voxilaprevir.

      Background & Aims

      Around 5% of patients with chronic hepatitis C virus (HCV) infection treated with direct-acting antiviral (DAA) agents do not achieve sustained virological response (SVR). The currently approved retreatment regimen for prior DAA failure is a combination of sofosbuvir, velpatasvir, and voxilaprevir (SOF/VEL/VOX), although there is little data on its use in clinical practice. The aim of this study was to analyse the effectiveness and safety of SOF/VEL/VOX in the real-world setting.


      This was a prospective multicentre study assessing the efficacy of retreatment with SOF/VEL/VOX in patients who had experienced a prior DAA treatment failure. The primary endpoint was SVR 12 weeks after the completion of treatment (SVR12). Data on safety and tolerability were also recorded.


      A total of 137 patients were included: 75% men, 35% with liver cirrhosis. Most were infected with HCV genotype (GT) 1 or 3. The most common prior DAA combinations were sofosbuvir plus an NS5A inhibitor or ombitasvir/paritaprevir/r+dasabuvir. A total of 136 (99%) patients achieved undetectable HCV RNA at the end of treatment. Overall SVR12 was 95% in the 135 patients reaching this point. SVR12 was lower in patients with cirrhosis (89%, p = 0.05) and those with GT3 infection (80%, p <0.001). Patients with GT3 infection and cirrhosis had the lowest SVR12 rate (69%). Of the patients who did not achieve SVR12, 1 was reinfected and 7 experienced treatment failure (6 GT3, 1 GT1a). The presence of resistance-associated substitutions did not impact SVR12. Adverse effects were mild and non-specific.


      Real-world data show that SOF/VEL/VOX is an effective, safe rescue therapy for patients with prior DAA treatment failure despite the presence of resistance-associated substitutions. However, patients with liver cirrhosis infected by GT3 remain the most-difficult-to-treat group.

      Lay summary

      Treatment with sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX) for 12 weeks is the current recommendation for the 5% of patients infected with HCV who do not achieve eradication of the virus under treatment with direct-acting antivirals. In a Spanish cohort of 137 patients who failed a previous combination of direct-acting antivirals, a cure rate of 95% was achieved with SOF/VEL/VOX. Genotypic characteristics of the virus (genotype 3) and the presence of cirrhosis were factors that decreased the rate of cure. Treatment with SOF/VEL/VOX is an effective and safe rescue therapy due to its high efficacy and very good safety profile.

      Graphical abstract


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Journal of Hepatology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Naggie S.
        • Muir A.J.
        Oral combination therapies for hepatitis C virus infection: successes, challenges, and unmet needs.
        Annu Rev Med. 2017; 68: 345-358
      1. EASL Recommendations on Treatment of Hepatitis C 2018. Journal of hepatology. 2018;69:461–511.

      2. Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology (Baltimore, Md). 2015;62(3):932–954.

      3. Hepatitis C Guidance 2018 Update: AASLD-IDSA recommendations for testing, managing, and treating hepatitis C virus infection. Clin Infect Dis. 2018;67(10):1477–1492.

        • Curry M.P.
        • O'Leary J.G.
        • Bzowej N.
        • Muir A.J.
        • Korenblat K.M.
        • Fenkel J.M.
        • et al.
        Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis.
        N Engl J Med. 2015; 373: 2618-2628
        • Ahmed H.
        • Abushouk A.I.
        • Attia A.
        • Gadelkarim M.
        • Gabr M.
        • Negida A.
        • et al.
        Safety and efficacy of sofosbuvir plus velpatasvir with or without ribavirin for chronic hepatitis C virus infection: a systematic review and meta-analysis.
        J Infect Public Health. 2018; 11: 156-164
        • D'Ambrosio R.
        • Pasulo L.
        • Puoti M.
        • Vinci M.
        • Schiavini M.
        • Lazzaroni S.
        • et al.
        Real-life effectiveness and safety of Glecaprevir/Pibrentasvir in 723 patients with chronic hepatitis C.
        J Hepatol. 2019; 70: 379-387
        • Chhatwal J.
        • Chen Q.
        • Ayer T.
        • Bethea E.D.
        • Kanwal F.
        • Kowdley K.V.
        • et al.
        Hepatitis C virus re-treatment in the era of direct-acting antivirals: projections in the USA.
        Aliment Pharmacol Ther. 2018; 47: 1023-1031
        • Lawitz E.
        • Yang J.C.
        • Stamm L.M.
        • Taylor J.G.
        • Cheng G.
        • Brainard D.M.
        • et al.
        Characterization of HCV resistance from a 3-day monotherapy study of voxilaprevir, a novel pangenotypic NS3/4A protease inhibitor.
        Antiviral Ther. 2018; 23: 325-334
        • Lawitz E.
        • Reau N.
        • Hinestrosa F.
        • Rabinovitz M.
        • Schiff E.
        • Sheikh A.
        • et al.
        Efficacy of sofosbuvir, velpatasvir, and GS-9857 in patients with genotype 1 hepatitis C virus infection in an open-label, phase 2 trial.
        Gastroenterology. 2016; 151: 893-901.e1
        • Lawitz E.
        • Poordad F.
        • Wells J.
        • Hyland R.H.
        • Yang Y.
        • Dvory-Sobol H.
        • et al.
        Sofosbuvir-velpatasvir-voxilaprevir with or without ribavirin in direct-acting antiviral-experienced patients with genotype 1 hepatitis C virus.
        Hepatology (Baltimore, MD). 2017; 65: 1803-1809
        • Bourliere M.
        • Gordon S.C.
        • Flamm S.L.
        • Cooper C.L.
        • Ramji A.
        • Tong M.
        • et al.
        Sofosbuvir, velpatasvir, and voxilaprevir for previously treated HCV infection.
        N Engl J Med. 2017; 376: 2134-2146
        • Bourliere M.
        • Gordon S.C.
        • Schiff E.R.
        • Tran T.T.
        • Ravendhran N.
        • Landis C.S.
        • et al.
        Deferred treatment with sofosbuvir-velpatasvir-voxilaprevir for patients with chronic hepatitis C virus who were previously treated with an NS5A inhibitor: an open-label substudy of POLARIS-1.
        Lancet Gastroenterol Hepatol. 2018; 3: 559-565
        • Sarrazin C.
        The importance of resistance to direct antiviral drugs in HCV infection in clinical practice.
        J Hepatol. 2016; 64: 486-504
        • Pawlotsky J.M.
        • Hepatitis C.
        Virus resistance to direct-acting antiviral drugs in interferon-free regimens.
        Gastroenterology. 2016; 151: 70-86
        • Lontok E.
        • Harrington P.
        • Howe A.
        • Kieffer T.
        • Lennerstrand J.
        • Lenz O.
        • et al.
        Hepatitis C virus drug resistance-associated substitutions: state of the art summary.
        Hepatology (Baltimore, MD). 2015; 62: 1623-1632
        • Scott L.J.
        Ledipasvir/sofosbuvir: a review in chronic hepatitis C.
        Drugs. 2018; 78: 245-256
        • Pol S.
        • Bourliere M.
        • Lucier S.
        • Hezode C.
        • Dorival C.
        • Larrey D.
        • et al.
        Safety and efficacy of daclatasvir-sofosbuvir in HCV genotype 1-mono-infected patients.
        J Hepatol. 2017; 66: 39-47
        • Al-Salama Z.T.
        • Deeks E.D.
        Elbasvir/grazoprevir: a review in chronic HCV genotypes 1 and 4.
        Drugs. 2017; 77: 911-921
        • Keating G.M.
        Ombitasvir/paritaprevir/ritonavir: a review in chronic HCV genotype 4 infection.
        Drugs. 2016; 76: 1203-1211
        • Deeks E.D.
        Ombitasvir/paritaprevir/ritonavir plus dasabuvir: a review in chronic HCV genotype 1 infection.
        Drugs. 2015; 75: 1027-1038
      4. EASL recommendations on treatment of hepatitis C 2014. Journal of hepatology. 2014;61(2):373–395.

        • De Ledinghen V.A.V.
        • Jose U.B.
        • Lucia P.
        • Jean-Baptiste H.
        • Giovanna S.
        • Wassil M.
        • Pageaux G.P.
        • Helen F.
        • Arlic L.
        • Hezode C.
        Sofosbuvir+Glecaprevir/Pibrentasvir in patients with difficult to treat HCV infection. Final results of the French compassionate use.
        J Hepatol. 2018; 68: 259
        • Wyles D.
        • Weiland O.
        • Yao B.
        • Weilert F.
        • Dufour J.F.
        • Gordon S.C.
        • et al.
        Retreatment of patients who failed glecaprevir/pibrentasvir treatment for hepatitis C virus infection.
        J Hepatol. 2019; 70: 1019-1023
        • Gottwein J.M.
        • Pham L.V.
        • Mikkelsen L.S.
        • Ghanem L.
        • Ramirez S.
        • Scheel T.K.H.
        • et al.
        Efficacy of NS5A inhibitors against hepatitis C virus genotypes 1–7 and escape variants.
        Gastroenterology. 2018; 154: 1435-1448
        • Belperio P.S.
        • Shahoumian T.
        • Loomis T.
        • Mole L.
        • Backus L.I.
        Real-world effectiveness of sofosbuvir/velpatasvir/voxilaprevir in 573 treatment-experienced patients with hepatitis C genotypes 1 through 4.
        Hepatology (Baltimore, MD). 2018; 68: 142A
        • Hezode C.
        • Guyader D.
        • Nguyen-Khac E.
        • Larrey D.
        • Régine T.
        • Di Martino V.
        • et al.
        Sofosbuvir + velpatasvir + voxilaprevir in Daa failure patients with cirrhosis. Final results of the french compassionate use program.
        Hepatology (Baltimore, MD). 2018; 68: 374A
        • Bacon B.R.C.M.
        • Flamm S.L.
        • Milligan S.
        • Naoky C.S.
        • Wick N.
        • Younossi Z.M.
        • et al.
        Sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX) in care of chronic hepatitis C patients; clinical practice experience from the trio network.
        Hepatology. 2018; 68: 419A
        • Vermehren J.S.A.
        • Zur Wiesch J.S.
        • Klinker H.
        • Cornberg M.
        • Jung M.C.
        • Simon K.G.
        • et al.
        Sarrazin C and german hepatitis registry retreatment with voxilaprevir/velpatasvir/sofosbuvir in patients with chronic hepatitis C virus infection and prior DAA failure – results from the german hepatitis C-registry (DHC-R).
        Hepatology. 2018; 68: 401A
        • Vermehren J.
        • Park J.S.
        • Jacobson I.M.
        • Zeuzem S.
        Challenges and perspectives of direct antivirals for the treatment of hepatitis C virus infection.
        J Hepatol. 2018; 69: 1178-1187
        • Sarrazin C.
        • Cooper C.L.
        • Manns M.P.
        • Reddy K.R.
        • Kowdley K.V.
        • Roberts S.K.
        • et al.
        No impact of resistance-associated substitutions on the efficacy of sofosbuvir, velpatasvir, and voxilaprevir for 12 weeks in HCV DAA-experienced patients.
        J Hepatol. 2018; 69: 1221-1230
        • Pearlman B.L.
        • Hinds A.
        • Perrys M.
        Sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX) for prior treatment failures with glecaprevir/pibrentasvir (G/P) in chronic hepatitis C infection.
        Hepatology (Baltimore, MD). 2018; 68: 361A
        • Covert E.H.J.
        • Comstock E.
        • Emmanuel B.
        • Tang L.
        • Kattakuzhy S.
        • Rosenthal E.
        • et al.
        Retreatment with SOF/VEL/VOX in treatment-experience patients with and without HIV: the resolve study.
        Hepatology. 2018; 68: 346A